Alsevalimab is being study as an experimental medicinal antibody targeting B7-H4 protein. The immunotherapy has shown preclinical potential in multiple malignant forms by reducing B7H4's activity in neoplastic spread https://fpa150320092.blognody.com/51824812/alsevalimab-a-new-b7-h4-protein-in-investigation